

Please amend claim 6 to read as follows:

6. (Amended) A composition of matter comprising a peptide consisting of at least the first ~~five~~ amino acids from the N-terminal of SEQ ID NO: 2 and no more than 25 amino acids.

Please amend claim 11 to read as follows:

11. (Amended) A composition of matter comprising of antibody made versus peptides containing from 5 to 15 amino acids from the N-terminal of SEQ ID NO: 2 for assaying NGF levels.

Please amend claim 12 to read as follows:

12. (Amended) A composition of matter comprising a peptide consisting of at least the first five amino acids from the N-terminal of SEQ ID NO: 2 and no more than 25 amino acids total.

Please amend claim 17 to read as follows:

17. (Amended) A method as in claim 16 wherein the nerve growth factor comprises a peptide consisting of

at least the first five amino acids from the N-terminal of SEQ ID NO: 2 and no more than 25 amino acids total.

Please amend claim 18 to read as follows:

18. (Amended) A process comprising contacting, in vitro, a human nerve growth factor with an antibody made against a peptide containing at least five amino acids from the N-terminal of SEQ ID NO: 2 and no more than 25 amino acids total.

Remarks


The claims have been amended to refer to their formerly recited sequences by "SEQ ID NO:" as required in the Office Action and 37 CFR 1.821(2)(d). The changes are shown in the attachment hereto by brackets and underlines. No new matter is presented. Reconsideration is requested.

Please mail correspondence to:

John R. Casperson
PO Box 2174
Friendswood, Texas 77549

Tel. No. 281-482-2961

Respectfully submitted:


John R. Casperson
Reg. No. 28,198